The global prostate cancer market is growing and is estimated to be worth USD 100 billion by 2026. More and more men are affected due to increased life expectancy.
A real clinical need
Today, the treatment of recurrent prostate cancer is controversial due to the severe side effects associated with several treatment options. Recurrent prostate cancer is our first prioritised indication.
A new treatment option
Our treatment method has the potential to become a beneficial alternative to other treatments, such as hormone therapy. Our method has the potential to cause fewer side effects and offer an improved quality of life.
Health economic viability
Our treatment method is designed to be less resource-consuming since our treatment is performed in a single session, allowing the patient to go home the same day.
Attractive business model with continuous revenue streams
The system is placed at the customer’s site for a low cost, providing a reduced barrier to entry. Recurring revenue is generated through the sale of sterile disposable equipment, with customers paying per treatment.
Potential to develop treatment for more cancer diagnoses
The treatment system has the potential to be suitable for treating several types of internal solid tumours, such as breast cancer.
SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects.